Tuesday, December 06, 2022
3:00 PM-4:00 PM ET
Arsalan "RC" Shah, PharmD, MBA
Senior Director of Pharmacy
Central City Concern
Portland, Oregon
Stacey B. Trooskin, MD, PhD, MPH
Chief Medical Officer
Philadelphia FIGHT Community Health Centers
Clinical Assistant Professor of Medicine
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania
Target Audience
The educational design of this activity addresses the needs of primary care, infectious disease, and public health and preventative medicine physicians, physician assistants, nurse practitioners, registered nurses, pharmacists, and social workers involved in the treatment of patients with HIV and HCV, specifically those experiencing homelessness.
Program Overview
Clinicians face multiple challenges in caring for people experiencing homelessness (PEH) who have or are risk for HIV and HCV. This unique population faces barriers to care such as lack of access to healthcare, lack of reliable means of contact, and multiple competing priorities. In this 1-hour webinar, Dr. Stacey Trooskin and Dr. Arsalan Shah will discuss screening for HIV and HCV and optimal strategies to link PEH to care, including how to incorporate community and outreach services and external partners. Clinic models for colocation services to simplify screening and linkage to care will be discussed.
Educational Objectives
After completing this activity, the participant should be better able to:
- Identify strategies to optimize outreach for HIV and HCV testing and linkage to care for PEH
- Identify key principles of harm reduction and trauma-informed care to optimize HIV and HCV care among PEH
- Identify community-based opportunities and logistics for colocation of HIV and HCV healthcare services with SUD and housing programs
Agenda
- 3:00 PM Welcome & Introduction
- 3:05 PM Determining the scope and configuration of your outreach services
- 3:20 PM Collaborating with external partners and colocation of services
- 3:35 PM Effective outreach models: Lining up your partners and resources to engage PEH
- 3:50 PM Question & Answer Session
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
Global is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
This educational activity for 1.0 contact hour is provided by Global. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacist Accreditation Statement
Global is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.
Credit Designation
Global designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0530-9999-22-100-L02-P)
This is a knowledge- based activity.
National Association of Social Workers
This activity is pending approval from the National Association of Social Workers.
Global Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.
Instructions to Receive Credit
In order to receive credit for this activity, the participant must attend the live webinar, and complete the posttest and program evaluation. Pharmacist learners must check CPE monitor within 30 days for their credit.
Fee Information& Refund/Cancellation Policy
There is no fee for this educational activity.
Disclosures of Conflicts of Interest
Global adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
We would like to thank HealthHIV and HealthHCV for their contributions and support.
This activity is jointly provided by Global Education Group and Integritas Communications.
This activity is supported by independent educational grants from AbbVie Inc., Gilead Sciences, Inc., and ViiV Healthcare. ViiV Healthcare was not involved in the development of content or selection of faculty for this educational activity.
Register Now


18
2025
Interleukin-33 and Lower Tract Respiratory Diseases
Moving From Pathophysiology to Management
Time: | 7:00 PM-8:30 PM PT |
Venue: | Live Stream |
Location: | Live Stream |
Faculty: | Jonathan M. Hand, MD; Professor Dave Singh MD, FERS, FBPhS; Professor Tom Wilkinson MA Cantab MBBS PhD FRCP FERS |


18
2025
Interleukin-33 and Lower Tract Respiratory Diseases
Moving From Pathophysiology to Management
Time: | 6:30 PM-8:30 PM PT |
Venue: | Marriott Marquis San Francisco, Yerba Buena 7 (Lower B2 Level) |
Location: | San Francisco, CA |
Faculty: | Professor Tom Wilkinson MA Cantab MBBS PhD FRCP FERS; Professor Dave Singh MD, FERS, FBPhS; Jonathan M. Hand, MD |
